2021-10-05| PartnerTechnology

CYTENA Bioprocess Solutions Closes $5M Funding to Develop Automatic High-throughput Screening Platform for Pharmaceuticals

by Kathy Huang
Share To
Charles Tsai, CEO of CYTENA BPS (left) and Elbert Chen, CFO of CYTENA BPS (right)

After obtaining $1.9 million in Pre-Seed round funding last November, CYTENA BPS closed $5 million series Pre-A funding in August 2021, led by German CYTENA GmbH part of the BICO Group. The main technologies developed by BICO and more specific business area Biosciences which CYTENA BPS belongs to are dedicated to promoting automated cell culture. BICO is the leading bio convergence company in the world.

Founded in 2018, CYTENA BPS (CYTENA BIOPROCESS SOLUTIONS) is an innovative company in Biosciences which specializes in automatic microbioreactor techniques. The company closed a financing round bringing in $5 million to further execute on the company’s long-term strategy and to develop a high put cell culture screening platform for pharmaceuticals.

By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, CYTENA BPS improves people’s health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.

With the increasing demand for pharmaceutical development, the trend of accelerating pharmaceutical processes with automation technology is inevitable. Via automatic cell culture devices, CYTENA BPS has a lot of possibilities of accelerating drug development.

CYTENA BPS will use the funds to integrate the current technology with automation and data analysis, further creating a high throughput screening platform for pharmaceuticals.

“With the latest financing, we hope to expand our team in the Asia Pacific region and actively seek more partnerships in the industry,” said Elbert Chen, CFO of CYTENA BPS.

CYTENA BPS’s launched a new micro-bioreactor in July earlier this year, the S.NEST. The patented technology keeps the cell floating in the culture medium and maximizes cell yield. In addition, the micro-bioreactor allows dynamic monitoring of dissolved oxygen and pH within the culture medium. This can stably maintain cell viability and allows for the production of monoclonal antibodies and protein drugs. The solutions of S.NEST increase the efficiency for selecting the best cell line in the early stage.

At CYTENA BPS we will continue to leverage our cell culturing techniques to develop novel techniques and equipment which will create value for our customers and researchers around the world,” said Charles Tsai, CEO of CYTENA BPS.

If you are interested to read more about CYTENA BPS or S. NEST please visit:


© All rights reserved. Collaborate with us:
Related Post
CYTENA BPS and Leadgene Bio to Level Up Taiwan’s Protein Drugs Production
CYTENA Launches the Next-Generation Microbioreactor to Revolutionize Cell Culture
Cytena Bioprocess Solutions Closes Pre-A series Funding, Accelerates Development in Microbioreactors
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
Breakthrough Zebrafish Genome Database Now Available
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
BIO Asia–Taiwan 2022
Online and on-side
ESMO 2022 Exhibition
Online and on-side
CSCO Educational Book 2022
RESI Boston
Human Gene Therapy Conference
Scroll to Top